Behrad Derakhshan, Ph.D., Chief Operating Officer, Edgewise Therapeutics (Photo: Business Wire) - Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer ...

- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading ...

Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...

Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...

These changes include the addition of Robert Blaustein, M.D., Ph.D., joining the Company as Chief Development Officer and the promotion of Behrad Derakhshan, Ph.D. from Chief Business Officer to Chief ...

- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo ...

Diese Führungsänderungen treten sofort in Kraft und spiegeln Edgewise's Engagement wider, seine Pipeline von Therapien für schwere Muskelerkrankungen voranzutreiben, einschließlich seines ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment with a market capitalization of $2.6 billion, today announced significant ...

The company has appointed Robert Blaustein, M.D., Ph.D., as Chief Development Officer (CDO) and promoted Behrad Derakhshan, Ph.D., to Chief Operating Officer (COO). Dr. Blaustein, with extensive ...